Neuroproteomics Methods and Protocols /

Detalles Bibliográficos
Autor Corporativo: SpringerLink (Online service)
Otros Autores: Ottens, Andrew K. (Editor ), Wang, Kevin K.W. (Editor )
Formato: eBook
Lenguaje:English
Publicado: Totowa, NJ : Humana Press : Imprint: Humana, 2009.
Edición:1st ed. 2009.
Colección:Methods in Molecular Biology, 566
Materias:
Acceso en línea:https://doi.org/10.1007/978-1-59745-562-6
Tabla de Contenidos:
  • Disease Models in Neuroproteomics
  • The Methodology of Neuroproteomics
  • Modeling Cerebral Ischemia in Neuroproteomics
  • Clinical and Model Research of Neurotrauma
  • Neuroproteomic Methods in Spinal Cord Injury
  • Modeling Substance Abuse for Applications in Proteomics
  • Protein Aggregate Characterization in Models of Neurodegenerative Disease
  • Sub-Proteome Separations and Neuroproteomic Analysis
  • Sub-Proteome Processing: Isolation of Neuromelanin Granules from the Human Bra
  • Proteomic Analysis of Protein Phosphorylation and Ubiquitination in Alzheimer's Disease
  • Proteomics Identification of Carbonylated and HNE-Bound Brain Proteins in Alzheimer's Disease
  • Mass Spectrometric Identification of In Vivo Nitrotyrosine Sites in the Human Pituitary Tumor Proteome
  • Improved Enrichment and Proteomic Analysis of Brain Proteins with Signaling Function by Heparin Chromatography
  • Calmodulin-Binding Proteome in the Bra
  • Neuroproteomic Methodology and Bioinformatics
  • Separation of the Neuroproteome by Ion Exchange Chromatography
  • iTRAQ-Based Shotgun Neuroproteomics
  • Methods in Drug Abuse Neuroproteomics: Methamphetamine Psychoproteome
  • Shotgun Protein Identification and Quantification by Mass Spectrometry in Neuroproteomics
  • Biofluid Analysis and Clinical Translation
  • Identification of Glycoproteins in Human Cerebrospinal Fluid
  • Mass Spectrometric Analysis of Body Fluids for Biomarker Discovery
  • Traumatic Brain Injury Biomarkers: From Pipeline to Diagnostic Assay Development
  • Translation of Neurological Biomarkers to Clinically Relevant Platforms.